SPOTLIGHT -
Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.
Bausch + Lomb announces results from a clinical study of a novel daily nutritional supplement for dry eyes
(EyePod) From idea to impact: Navigating ophthalmic innovation
The Fred Hollows Foundation supporting 2030 IN SIGHT LIVE
EyePod: Modifier Gene Therapy: What is it?
Verana Health launches its Qdata Thyroid Eye Disease module
Gene editing untangles one strand of the AMD web